A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting - Regional Cancer Care Associates LLC

Clinical Trials

A Phase 2, Multicenter, Single-arm, Open-Label Study of Pomalidomide in Combination with Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Following Lenalidomide plus Dexamethasone in the Second Line Setting

Type of Cancer
Multiple Myeloma
Locations
Hackensack
Sponsor
Celgene
Protocol Number
CC-4047-MM-014
Cancer Diagnosis
To Learn More Call
201-510-0910